title: [A clinical study in postoperative bile excretion of cefuzonam].
abstract: We investigated the postoperative bile excretion and serum concentration of cefuzonam (CZON) in 6 cholecystectomized patients with postsurgical biliary drainage. CZON was administered intravenously by infusion at a dose of 1.0 g immediately following the operation. Serum and bile concentrations of CZON were determined on the day of the operation and the second day after the operation. The following results were obtained. 1. Serum concentrations of CZON were at their highest levels at 30 minutes after administration of CZON. Levels were 45.8 +/- 13.8 micrograms/ml on the day of the operation and 60.9 +/- 12.2 micrograms/ml on the second postsurgical day. 2. Bile concentration peaked 1 hour after administration (4,083 +/- 1,427 micrograms/ml on the day of the operation and 4,376 +/- 630 micrograms/ml on the second postsurgical day). In particular, bile concentrations of CZON at 6 hours (259 +/- 140 micrograms/ml and 154 +/- 23 micrograms/ml) exceeded MIC80 of CZON against Gram-negative bacteria except for Pseudomonas aeruginosa. 3. Serum and bile concentrations were higher on the second postsurgical day than on the day of the operation, but the differences between these 2 days were not significant. These results have indicated that CZON is a useful drug with excellent bile excretion following cholecystectomy, and that bile concentrations of CZON are maintained at high levels for 6 hours after intravenous administration.
authors.affiliation: Second Department of Surgery, Shiga University of Medical Science.
authors.forename: M
authors.initials: M
authors.lastname: Hirano
authors.forename: M
authors.initials: M
authors.lastname: Fujimura
authors.forename: A
authors.initials: A
authors.lastname: Yamamoto
authors.forename: I
authors.initials: I
authors.lastname: Yamamoto
authors.forename: K
authors.initials: K
authors.lastname: Nishimura
authors.forename: H
authors.initials: H
authors.lastname: Takahara
authors.forename: T
authors.initials: T
authors.lastname: Hirano
authors.forename: A
authors.initials: A
authors.lastname: Mori
mesh_terms: D000328:Adult; D000368:Aged; D001424:Bacterial Infections; D001646:Bile / Q000378:metabolism*; D015296:Ceftizoxime / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D002763:Cholecystectomy; D002764:Cholecystitis / Q000382:microbiology / Q000517:prevention & control; D002769:Cholelithiasis / Q000378:metabolism* / Q000601:surgery; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000517:prevention & control; D011292:Premedication
chemical_list: C049934:cefuzonam; D015296:Ceftizoxime